First Clinical Trial in MOGAD Meets Primary Endpoint
04/05/2026
Introducción The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial of myelin oligodendrocyte
Introducción The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial of myelin oligodendrocyte
A novel strategy for switching breast cancer therapy intrigued members of an FDA advisory committee but failed to sway the
Introducción A dedicated bipolar implantable cardioverter-defibrillator (ICD) lead for conduction system pacing (CSP) performed well in a first-in-human multicenter study.
Artificial Intelligence in Oncology Could the growing influence of artificial intelligence (AI) in healthcare lead to a license to practice
Introducción Autosomal recessive nonsyndromic hearing loss 9 (DFNB9) is a rare genetic condition caused by mutations in the OTOF gene,